ECSP22041169A - Anticuerpos trem2 y usos de estos - Google Patents

Anticuerpos trem2 y usos de estos

Info

Publication number
ECSP22041169A
ECSP22041169A ECSENADI202241169A ECDI202241169A ECSP22041169A EC SP22041169 A ECSP22041169 A EC SP22041169A EC SENADI202241169 A ECSENADI202241169 A EC SENADI202241169A EC DI202241169 A ECDI202241169 A EC DI202241169A EC SP22041169 A ECSP22041169 A EC SP22041169A
Authority
EC
Ecuador
Prior art keywords
trem2 antibodies
trem2
antibodies
diseases
relates
Prior art date
Application number
ECSENADI202241169A
Other languages
English (en)
Inventor
Ying Tang
Forest Hoyt Andrews
Ross Edward Fellows
Yaming Wang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP22041169A publication Critical patent/ECSP22041169A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos TREM2 y usos de estos para tratar enfermedades tales como enfermedades neurodegenerativas.
ECSENADI202241169A 2019-11-22 2022-05-20 Anticuerpos trem2 y usos de estos ECSP22041169A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962939097P 2019-11-22 2019-11-22

Publications (1)

Publication Number Publication Date
ECSP22041169A true ECSP22041169A (es) 2022-06-30

Family

ID=73790267

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202241169A ECSP22041169A (es) 2019-11-22 2022-05-20 Anticuerpos trem2 y usos de estos

Country Status (17)

Country Link
US (1) US20220281975A1 (es)
EP (1) EP4061842A1 (es)
JP (1) JP7368624B2 (es)
KR (1) KR20220084152A (es)
CN (1) CN114667295B (es)
AU (1) AU2020387380A1 (es)
BR (1) BR112022007944A2 (es)
CA (1) CA3159055A1 (es)
CO (1) CO2022006708A2 (es)
CR (1) CR20220228A (es)
DO (1) DOP2022000104A (es)
EC (1) ECSP22041169A (es)
IL (1) IL293018A (es)
JO (1) JOP20220119A1 (es)
MX (1) MX2022006145A (es)
PE (1) PE20221337A1 (es)
WO (1) WO2021101823A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4066859A1 (en) 2014-08-08 2022-10-05 Alector LLC Anti-trem2 antibodies and methods of use thereof
CN108738323B (zh) * 2015-10-06 2023-05-26 艾利妥 抗trem2抗体及其使用方法
CN109641961A (zh) * 2016-07-22 2019-04-16 德国神经退行性疾病研究中心 Trem2切割调节剂及其用途
CR20230170A (es) 2017-08-03 2023-05-31 Alector Llc ANTICUERPOS ANTI-TREM2 Y MÉTODOS PARA UTILIZARLOS (divisional 2019-0485)
US20200277373A1 (en) * 2017-09-14 2020-09-03 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
CR20200303A (es) * 2017-12-12 2020-12-23 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y métodos relacionados

Also Published As

Publication number Publication date
PE20221337A1 (es) 2022-09-13
JOP20220119A1 (ar) 2023-01-30
AU2020387380A1 (en) 2022-05-26
CA3159055A1 (en) 2021-05-27
MX2022006145A (es) 2022-06-17
US20220281975A1 (en) 2022-09-08
KR20220084152A (ko) 2022-06-21
JP2023502460A (ja) 2023-01-24
DOP2022000104A (es) 2022-07-31
CO2022006708A2 (es) 2022-05-31
CN114667295A (zh) 2022-06-24
BR112022007944A2 (pt) 2022-07-12
JP7368624B2 (ja) 2023-10-24
EP4061842A1 (en) 2022-09-28
CR20220228A (es) 2022-06-08
IL293018A (en) 2022-07-01
CN114667295B (zh) 2024-03-29
WO2021101823A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
ECSP20075198A (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos
ECSP22041169A (es) Anticuerpos trem2 y usos de estos
CL2016002509A1 (es) Composiciones para modular la expresión de sod-1
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
GT201700188A (es) Anticuerpos contra tau y sus usos
ECSP19020740A (es) Anticuerpos anti-cd27
CL2021001573A1 (es) Anticuerpos anti-muc16 x anti-cd28 biespecíficos y usos de estos.
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
EA201890093A1 (ru) Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
CR20180077A (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CL2016002281A1 (es) Anticuerpos de il-21
CL2018000611A1 (es) Sales de un inhibidor de pim quinasa
UY37980A (es) Compuestos novedosos para tratar enfermedades parasitarias
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
PE20201343A1 (es) Anticuerpos anti-trem-1 y usos de los mismos
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
BR112022009493A2 (pt) Fabricação de do3a protegido
BR112018005999A2 (pt) métodos para a produção de intermediários de onapristona
BR112022004475A2 (pt) Proteínas de fusão nkg2d e usos das mesmas
EA201790428A1 (ru) Синтез энт-прогестерона и его промежуточных соединений
CL2017002304A1 (es) Métodos para tratar enfermedades
CO2022015030A2 (es) Anticuerpos anti-cd19 y sus usos